Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study
- PMID: 17371352
- DOI: 10.1111/j.1526-4610.2006.00631.x
Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study
Erratum in
- Headache. 2007 Oct;47(9):1365
Abstract
Objective: To describe the patterns of medical treatment for migraineurs in the United States.
Background: Over the past decade, many new treatments for migraine have become available and awareness of migraine has improved. However, there is little information about the patterns of medical treatment in the US society.
Design/methods: A validated self-administered headache questionnaire was mailed to a random sample of 120,000 US households. Each household member with severe headaches was asked to complete the survey. The questionnaire assessed headache features, disability, and patterns of medical treatment. Subjects were classified according to their use of headache preventive medication, as current users, coincident users (using effective medications for other medical reasons), lapsed users (had used in the past but not at the time of the survey), or never users.
Results: In 162,576 participants, the prevalence of migraine was 17.1% in women and 5.6% in men. Only 56.2% of those with migraine had ever received a medical diagnosis. Ninety-eight percent of the migraineurs used acute treatment for their migraine attacks. Forty-nine percent (49%) usually used over-the-counters, 20% usually used prescription medications, and 29% used both. Only 12.4% of migraineurs indicated that they were taking a migraine preventive medication, but 17.2% were using medications with potential antimigraine effects for other medical reasons. Current or past use of preventive medication was more likely in women than men (odds ratio [OR] = 1.37, 95% confidence interval [CI] 1.27-1.48), increased with age and individuals with high MIDAS grade (Grade IV vs I, OR 2.35, 95% CI 2.09-2.64). Preventive medication use increased with awareness of migraine and with illness severity.
Conclusions: Migraine remains undertreated in the US population. Barriers to preventive treatment are greater in younger age groups, men, and people unaware that they have migraine.
Similar articles
-
Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study.Cephalalgia. 2007 Mar;27(3):220-9. doi: 10.1111/j.1468-2982.2006.01275.x. Cephalalgia. 2007. PMID: 17263769
-
A pivotal moment in 50 years of headache history: the first American Migraine Study.Headache. 2008 May;48(5):730-1; discussion 732. doi: 10.1111/j.1526-4610.2008.01117_1.x. Headache. 2008. PMID: 18471125
-
Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey.Headache. 2006 May;46(5):715-25. doi: 10.1111/j.1526-4610.2006.00430.x. Headache. 2006. PMID: 16643573
-
Migraine in the United States: a review of epidemiology and health care use.Neurology. 1993 Jun;43(6 Suppl 3):S6-10. Neurology. 1993. PMID: 8502385 Review.
-
The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.Headache. 2013 Mar;53(3):427-36. doi: 10.1111/head.12074. Epub 2013 Mar 7. Headache. 2013. PMID: 23470015 Review.
Cited by
-
Association between severe headache or migraine and erectile dysfunction in American adults: a cross-sectional of data study from the NHANES.Int J Impot Res. 2024 Apr 12. doi: 10.1038/s41443-024-00867-w. Online ahead of print. Int J Impot Res. 2024. PMID: 38609543
-
Migraine Management in Community Pharmacies: Knowledge, Attitude and Practice Patterns of Pharmacists in Saudi Arabia.Pharmacy (Basel). 2023 Sep 24;11(5):155. doi: 10.3390/pharmacy11050155. Pharmacy (Basel). 2023. PMID: 37888500 Free PMC article.
-
Managing migraine on the frontline: Identifying disease, understanding burden, and incorporating CGRP pathway-targeting therapies in primary care.Br J Pain. 2022 Oct;16(5):560-573. doi: 10.1177/20494637221104292. Epub 2022 May 29. Br J Pain. 2022. PMID: 36389011 Free PMC article.
-
Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.Health Psychol Res. 2022 Nov 12;10(5):38439. doi: 10.52965/001c.38439. eCollection 2022. Health Psychol Res. 2022. PMID: 36381178 Free PMC article.
-
Rimegepant for the treatment of migraine.Health Psychol Res. 2022 Oct 12;10(5):38534. doi: 10.52965/001c.38534. eCollection 2022. Health Psychol Res. 2022. PMID: 36262478 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous